The results of this study demonstrated that CDCA2 might target CCND1 to promote CRC cell proliferation and tumorigenesis at least partially through activation of the PI3K/AKT pathway, and CDCA2 might serve as a potential prognostic and therapeutic target for CRC. Here, AKT1 is linked to colorectal carcinoma.